Mursla Bio’s AI Precision Medicine Platform unlocks organ-specific molecular insights from a simple blood sample, providing biologically labelled, multi-omics data with the resolution of tissue biopsy without its invasiveness. For more details, please refer to our pre-print.

Pharmaceutical partners can use this to stratify patients more effectively, monitor therapeutic response in vivo, and identify novel surrogate endpoints across complex disease areas.

The platform has already powered a first-in-class IVD for liver cancer that received FDA Breakthrough Device Designation and is now being extended to cardiometabolic, lung, and neurological indications.

Find out more here.